Prescient Therapeutics Ltd has released a press release.
PTX-100 trial advances following successful Phase 1b
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- PTX successful immunogenicity testing of OmniCAR
- PTX Completes CAR-T Manufacturing Milestone for OmniCAR
- Response to ASX Price Query
- PTX signs CAR-T agreement with Peter MacCallum
- March 2021 Quarterly Update and Appendix 4C
Later from Prescient Therapeutics
- June 2021 Quarterly Activities and Appendix 4C
- Appendix 4E and 2021 Annual Report
- PTX data demonstrates key OmniCAR features in next gen CAR-T
- Investor Presentation - October 2021
- September 2021 Quarterly Activities and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics